Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E4/DRSP versus Yaz for ovarian suppression in contraception
NL-OMON43032Phase 2Active, not recruiting
- Sponsor
- Estetra SRL
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of estetrol, drospirenone and ethinyl estradiol in contraception (2 arms), sponsored by Estetra SRL. Primary endpoints: Ovarian suppression at Treatment Cycle 1 and Ovarian suppression at Treatment Cycle 3. Started Feb 2017; status: active, not recruiting.
02
Drugs
estetroldrospirenoneethinyl estradiol
03
Conditions
contraception
Beyond the preview
Go deeper on NL-OMON43032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43032.